Ovarian cancer is the leading cause of death from gynaecological malignancies, with approximately 21 550 new cases and 14 600 deaths occurring annually in the United States ([@bib10]). Over the past two decades, the first-line chemotherapeutic drugs for treating epithelial ovarian cancer have been the platinum-based drug cisplatin and taxanes such as paclitaxel ([@bib20]; [@bib5]). Most patients respond well initially to platinum and taxane-based therapies, unfortunately resistance frequently ensues. Moreover, the major limitation of conventional chemotherapy is severe toxicity to normal tissues resulting from a lack of selectivity towards cancer cells. Thus, cancer-selective targeting has been recognised as an important goal in developing new therapeutics ([@bib23]).

In this study, we used a new strategy to deliver anticancer drugs selectively into ovarian tumour cells by targeting sigma-2 receptors. The sigma-2 receptor is overexpressed in various human tumours ([@bib2]; [@bib30]; [@bib31]). Our group has previously validated the sigma-2 receptor as a biomarker for imaging proliferating tumour cells ([@bib11]; [@bib35]). The density of sigma-2 receptors in proliferative tumour cells is approximately 10-fold higher than in nonproliferative or quiescent tumour cells in cell culture and in solid tumours. Sigma-2 receptor-selective radiotracers, developed in our laboratory, have been shown to target various solid tumours in rodents and in human patients using the functional imaging technique, positron emission tomography (PET), and the uptake of the sigma-2-selective radiotracer \[^18^F\]ISO-1 correlated with the Ki-67 score in lymphoma, head and neck, and breast cancer patients ([@bib24], [@bib25]; [@bib3]). These data demonstrate that sigma-2 receptor ligands possess high selectivity for tumour cells *vs* normal tissues *in vivo*. In addition, we have previously demonstrated that the fluorescent sigma-2 receptor probe, **SW 120**, is rapidly internalised into cancer cells by an endocytotic pathway and localises in multiple subcellular organelles such as mitochondria and endoplasmic reticulum ([@bib40], [@bib39]), suggesting that sigma-2 receptor ligands are excellent candidates to deliver anticancer drugs selectively into tumours. This sigma-2 receptor-targeting strategy has shown the initial success in pancreatic tumour xenograft mouse models ([@bib19]). Recently, our group has identified progesterone receptor membrane component 1 as the potential sigma-2 receptor ([@bib37]). This finding will facilitate further investigations of sigma-2 receptor-selective ligands for imaging, therapeutic and drug delivery applications.

Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria into the cytosol in response to apoptotic stimuli ([@bib6]; [@bib18]). Smac protein promotes apoptosis through binding to and antagonising the activity of inhibitor of apoptosis proteins (IAPs) including XIAP, cIAP-1 and cIAP-2, thus relieving them of their caspase-binding partners and sensitising cells to apoptosis. XIAP binds and inhibits caspase-9 through its baculovirus IAP repeat (BIR) 3 domain and caspase-3/7 through its BIR2 domain together with the linker before BIR2. Smac interacts with the BIR2 or BIR3 domain of IAPs via the AVPI tetrapeptide-binding motif on the N-terminus of Smac. Small-molecule Smac mimetic compounds (SMC) have been developed by imitating the AVPI-binding motif of Smac ([@bib21]). SMC have been shown to sensitise tumour cells to other anticancer drugs as well as to induce apoptosis as single agents in a subset of tumour cells ([@bib13]; [@bib15]; [@bib28]; [@bib32]; [@bib21]; [@bib34]; [@bib14]). SMC have been introduced in phase I clinical trials ([@bib7]). However, a recent report indicated that SMC can increase tumour metastasis in the bone via osteoclast activation ([@bib38]). Therefore, it is important that SMC is delivered specifically into tumour cells rather than normal tissues such as bone. In this study, we aimed to use a sigma-2 ligand to deliver SMC into ovarian cancer cells. We have conjugated a sigma-2 ligand, **SW 43**, to a SMC, **SW IV-52s**, to form a sigma-2 receptor ligand-conjugated SMC, **SW III-123**. We have shown that the sigma-2 ligand effectively delivers SMC into ovarian cancer cells and potently induces cell death. **SW III-123** induced degradation of cIAP1 and cIAP2, NF-*κ*B activation, and tumour necrosis factor alpha (TNF*α*)-dependent apoptosis in SKOV-3 cells, likely representing a novel class of therapeutic drugs for treating ovarian cancer.

Materials and methods
=====================

Chemical synthesis of SW III-123 and SW IV-52s
----------------------------------------------

^1^H NMR spectra were recorded on a Varian 300 MHz NMR spectrometer (Varian, Inc., Walnut Creek, CA, USA). Chemical shifts are reported in *δ* values (parts per million) relative to an internal standard of tetramethylsilane. The following abbreviations are used for multiplicity of NMR signals: br s=broad singlet, d=doublet, m=multiplet, s=singlet. Melting points were determined on an electrothermal melting point apparatus and are uncorrected. Elemental analyses were performed by Atlantic Microlab, Inc., Norcross, GA, USA and were within±0.4% of the calculated values. Mass spectrometry was provided by the Washington University Mass Spectrometry Resource (Washington University, St Louis, MO, USA). All reactions were carried out under an inert atmosphere of nitrogen.

### General procedure for peptide coupling

1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI; 1.1 eq) was added to a stirred solution of the Boc-protected amino acid, *N*,*N*-diisopropylethylamine (DIPEA; 1.1 eq) and 1-hydroxybenzotriazole (HOBt; 1.1 eq) in DMF (15 ml) at 0 °C. After 5 min, the amino component (1.1 eq) was added to the ice-cold solution, and the reaction mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc and washed with 2% HCl solution, saturated NaHCO~3~ solution and brine, respectively. The organic layer was dried over Na~2~SO~4~, and the volatiles were removed under reduced pressure. The Boc-protected coupling product was purified by column chromatography (silica gel, EtOAc: hexane=1 : 2).

### General procedure for removal of the Boc-protecting group

The Boc-protected compound was stirred with trifluoroacetic acid in dichloromethane (1 : 2) for 5 h at room temperature. The volatiles were removed under reduced pressure, and the residue was basified with saturated Na~2~CO~3~ solution, extracted with dichloromethane, dried over Na~2~SO~4~, filtered and evaporated to give the product.

### (*S*)-*N*-((*R*)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine-2-carboxamide (3)

Using the general procedure for peptide coupling and Boc removal, compound **3** was synthesised from Boc-proline (Pro)-OH (**1**) and R-(-)-1,2,3,4-tetrahydro-1-napthylamine (**2**) as an off-white powder (83% yield), mp 81--82 °C. ^1^H NMR (CDCl~3~) *δ* 7.90 (d, *J*=8.8 Hz, 1H), 7.09--7.17 (m, 4H), 5.10--5.16 (m, 1H), 3.28--3.87 (m, 1H), 2.97--3.02 (m, 1H), 2.73--2.90 (m, 4H), 1.98--2.21 (m, 3H), 1.70--1.87 (m, 5H).

### *(S)-1-*((*S*)-2-amino-3,3-dimethylbutanoyl)-*N*-((*R*)-1,2,3,4-tetrahydronaphthalen-1-yl) pyrrolidine-2-carboxamide (4)

Using the general procedure for peptide coupling and Boc removal, compound **4** was synthesised from **3** and Boc-*tert*-leucine/*tert*-butylglycine (Tle)-OH as an off-white solid (78% yield), mp 143--144 °C. ^1^H NMR (CDCl~3~) *δ* 7.41 (d, *J*=8.5 Hz, 1H), 7.04--7.21 (m, 4H), 5.09--5.14 (m, 1H), 4.63--4.66 (m, 1H), 3.55--3.60 (m, 2H), 2.73--2.80 (m, 2H), 2.47--2.54 (m, 1H), 2.11--2.17 (m, 1H), 1.80--2.01 (m, 7H), 1.51 (br s, 2H), 0.80 (s, 9H).

### (*2S*)-1-((*2S*)-2(2-chloropropanamido)-3,3-dimethylbutanoyl)-*N*-((*R*)-1,2,3,4-tetrahydro-naphthalen-1-yl)pyrrolidine-2-carboxamide (5)

A mixture of compound **4**, 2-chloropropionyl chloride (1.2 eq) and triethylamine (3 eq) in dichloromethane (15 ml) was stirred at room temperature for 4 h, followed by adding saturated aqueous NaHCO~3~ and stirred for 30 min. The organic layer was separated and evaporated. The resulting residue was purified by column chromatography (5% methanol in dichloromethane) to give **5** as a light yellow solid (81% yield), mp 158--159 °C. ^1^H NMR (CDCl~3~) *δ* 7.22--7.25 (m, 1H), 7.04--7.16 (m, 4H), 5.10--5.16 (m, 1H), 4.55--4.61 (m, 2H), 4.34--4.46 (m, 1H), 3.63--3.76 (m, 2H), 2.73--2.80 (m, 2H), 2.42--2.48 (m, 1H), 1.83--2.17 (m, 7H), 1.69--1.73 (m, 3H), 0.86 (s, 9H).

### 9-(10((-1-(((*S*)-3,3-dimethyl-1-oxo-1-((S)-2-(((*R*)-1,2,3,4-tetrahydro-naphthalen-1-yl) carbamoyl)pyrrolidin-1-yl)butan-2-yl)amino)-1-oxopropan-2-yl)amino)decyl)-9-azabicyclo \[3.3.1\]nonan-3-yl(2-methoxy-5-methylphenyl) carbamate (SW III-123)

A mixture of **SW43** (350 mg, 0.8 mmol), **5** (340 mg, 0.8 mmol) and triethylamine (230 mg, 2.3 mmol) in THF (7 ml) was heated at 65--70 °C for 6 days and evaporated. The resulting residue was purified by column chromatography (8% methanol in dichloromethane) to give **SW III-123** as an off-white powder (137 mg, 31% yield), mp 66-67 °C. ^1^H NMR (CDCl~3~) *δ* 7.89--7.95 (m, 2H), 7.22--7.29 (m, 2H), 7.04--7.14 (m, 4H), 6.73--6.80 (m, 2H), 5.10--5.18 (m, 2H), 4.52--4.61 (m, 2H), 3.85 (s, 3H), 3.77--3.82 (m, 1H), 3.59--3.66 (m, 1H), 3.09--3.16 (m, 3H), 2.44--2.79 (m, 9H), 2.30 (s, 3H), 1.81--2.20 (m, 9H), 1.27--1.62 (m, 23H), 1.24 (d, *J*=6.9 Hz, 3H), 0.85 (s, 9H).

### (*S*)-1-((*S*)-3,3-dimethyl-2-((*S*)-2-(methylamino)propanamido)butanoyl)-*N*-((*R*)-1,2,3,4-terahydronaphthalen-1-yl)pyrrolidine-2-carboxamide oxalate (SW IV-52S)

Using the general procedure for peptide coupling from **4** and Boc-*N*-Me-alanine (Ala)-OH, followed by Boc removal gave the product as a free amine (55% yield). ^1^H NMR (CDCl~3~) *δ* 7.74 (d, *J*=9.8 Hz, 1H), 7.22--7.24 (m, 2H), 7.04--7.14 (m, 3H), 5.12--5.14 (m, 1H), 4.58--4.61 (m, 1H), 4.55 (d, *J*=9.8 Hz, 1H), 3.79--3.84 (m, 1H), 3.64--3.67 (m, 1H), 3.05--3.07 (m, 1H), 2.73--2.79 (m, 2H), 2.43--2.47 (m, 1H), 2.34 (s, 3H), 2.10--2.18 (m, 1H), 1.95--2.01 (m, 2H), 1.82--1.89 (m, 4H), 1.56 (br s, 1H), 1.28 (d, *J*=7.1 Hz, 3H), 0.85 (s, 9H). The oxalate salt was prepared using 1 equivalent of oxalic acid in ethanol to give **SW IV-52s** as a light yellow solid, mp 148--149 °C. MS *m/z*=443 (M+H)^+^. HRMS for \[C~25~H~39~N~4~O~3~\]^+^ 443.3022; found: 443.3038. Anal. (C~27~H~40~N~4~O~7~, 0.5H~2~O): calculated, %: C 59.87; H 7.63; N 10.34; found, %: C 59.54, H 7.45, N 10.18.

Receptor-binding assays
-----------------------

The sigma-1 and sigma-2 receptor-binding affinities of **SW III-123** were determined as previously described ([@bib36]). Briefly, guinea pig brain (sigma-1 assay) or rat liver (sigma-2 assay) membrane homogenates (∼300 *μ*g protein) were diluted with 50 m[M]{.smallcaps} Tris-HCl, pH 8.0 and incubated with either ∼5 n[M]{.smallcaps} \[^3^H\](+)-pentazocine (34.9 Ci mmol^--1^; sigma-1 assay) or 1 n[M]{.smallcaps} \[^3^H\]RHM-1 (80 Ci mmol^--1^; sigma-2 assay) in a total volume of 150 *μ*l in 96-well plates at 25 °C. The concentrations of **SW III-123** ranged from 0.1 n[M]{.smallcaps} to 10 *μ*[M]{.smallcaps}. After incubating for 60 min, the reactions were terminated by the addition of 150 *μ*l of cold wash buffer (10 m[M]{.smallcaps} Tris-HCl, 150 m[M]{.smallcaps} NaCl, pH 7.4) using a 96-channel transfer pipette (Fisher Scientific, Pittsburgh, PA, USA), and the samples harvested and filtered rapidly into a 96-well fiberglass filter plate (Millipore, Billerica, MA, USA) that had been presoaked with 100 *μ*l of 50 m[M]{.smallcaps} Tris-HCl, at pH 8.0 for 1 h. Each filter was washed three times with 200 *μ*l of ice-cold wash buffer, and the bound radioactivity quantified using a Wallac 1450 MicroBeta liquid scintillation counter (Perkin Elmer, Boston, MA, USA). Nonspecific binding was determined in the presence of 10 *μ*[M]{.smallcaps} cold haloperidol.

Cell culture conditions
-----------------------

The SKOV-3 human ovarian cancer cell line was cultured in 5A McCoy\'s medium containing 10% fetal bovine serum (FBS), 2 m[M L]{.smallcaps}-glutamine, and 100 units ml^--1^ penicillin and 100 μg ml^--1^ streptomycin. The CaOV-3 human ovarian cancer cell line was cultured in DMEM containing 10% FBS, 2 m[M L]{.smallcaps}-glutamine, 100 units ml^--1^ penicillin and 100 μg ml^--1^ streptomycin. The BG-1 human ovarian cancer cell line was cultured in DMEM/F-12 containing 10% FBS, 2 m[M L]{.smallcaps}-glutamine, 100 units ml^--1^ penicillin and 100 μg ml^--1^ streptomycin. Cells were maintained in a humidified incubator at 37 °C in a 5% CO~2~ atmosphere.

MTS cell proliferation assay
----------------------------

The cytotoxicity of the compounds on SKOV-3, CaOV-3 and BG-1 human ovarian cancer cell lines was measured by the MTS assay. The MTS assay was performed using the CellTiter 96 Aqueous One Solution Assay (Promega, Madison, WI, USA) which contains a tetrazolium compound \[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS\], according to the manufacturer\'s protocol. Briefly, cells were plated 4 × 10^3^ cells per well in 96-well plates 24 h before treatment with the compounds. Each compound was dissolved in DMSO and serially diluted in culture medium to acquire the desired concentrations. The final concentration of DMSO in the cell culture medium was no more than 1.0%. After a 24- or 48-h treatment with the various compounds, 20 *μ*l of the CellTiter 96 aqueous one solution reagent was added to each well, and the plate was incubated for 1--2 h at 37 °C. The plate was then read at 490 nm in a Victor^3^ plate reader (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). The EC~50~, defined as the concentration of the sigma ligand required to inhibit cell proliferation by 50% relative to untreated cells, was determined from the dose-response curves generated using GraFit software, version 5 (Erithacus Software Limited, West Sussex, UK). All the compounds were assayed in triplicate, and the EC~50~ values presented as the mean±s.e.m. of three independent experiments.

Caspase-3 cell assay
--------------------

The caspase-3 activity induced by the compounds in SKOV-3 cells was measured using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega). This assay utilises a profluorescent substrate Z-DEVD-R110 specific for caspase-3/7 coupled with an optimised cell permeabilisation buffer. Cleavage of the peptide sequence DEVD by active caspase-3/7 releases free Rhodamine 110, which when excited at 485 nm, becomes intensely fluorescent and can be detected at emission wavelength 535 nm. The amount of fluorescent product generated is directly proportional to the caspase-3/7 activity in each sample. SKOV-3 cells were plated 4 × 10^3^ cells per well in 96-well black, clear-bottomed plates 24 h before treatment with the compounds. After a 24-h treatment with the various compounds, caspase-3 activity was assessed using the Apo-ONE Homogeneous Caspase-3/7 Assay. In all, 10 ml of buffer was pre-mixed with 100 *μ*l of the caspase-3/7 substrate Z-DEVD-R110. In total, 100 *μ*l of the substrate-buffer mix was added to each well and the plate was placed on an orbital shaker for 5 min. The plate was then incubated at room temperature in the dark for up to 18 h. The plate was then read at excitation and emission wavelengths 485 and 535 nm, respectively, on a Victor^3^ plate reader (PerkinElmer Life and Analytical Sciences). Caspase-3 activation was determined by comparing maximal response values with untreated controls and results were plotted as increase over baseline.

Blocking studies of internalisation of SW 120 in SKOV-3 cells
-------------------------------------------------------------

SKOV-3 cells were plated in 100 mm dishes at 5 × 10^5^ cells per dish for 24 h before treatment with compounds. The cells were incubated with 0, 0.3, 1, 3 and 10 *μ*[M]{.smallcaps} **SW 43**, **SW IV-52s** or **SW III-123** for 30 min at 37 °C. In all, 10 n[M]{.smallcaps} **SW 120** was then added to the cell culture dishes containing the above blocking compounds. After 30-min incubation at 37 °C, the cells were washed with phosphate-buffered saline (PBS) twice and detached with 0.05% trypsin-EDTA (Life Technologies, Grand Island, NY, USA). The cells were centrifuged at 1000 × **g** for 5 min. The cell pellets were washed with PBS twice. Internalisation of **SW 120** into the cells was analysed by flow cytometer. Flow Cytometric analysis was performed using a FACScan DxP10 (BD Bioscience, San Jose, CA, USA, and Cytek Development, Fremont, CA, USA), equipped with a 30 mW Coherent Sapphire solid state 488 nm laser to excite **SW 120**. Emission was captured with a 530/30 bandpass filter.

Western blot analysis
---------------------

SKOV-3 cells (1 × 10^6^ per dish) were plated in 100 mm culture dishes 24 h before drug treatment. For dose-response experiments, cells were treated with 0, 1, 3 or 10 *μ*[M]{.smallcaps} **SW 43**, **SW IV-52s** or **SW III-123** for 24 h. For time course experiments, cells were treated with 3 *μ*[M]{.smallcaps} **SW 43**, **SW IV-52s** or **SW III-123** for 0, 0.5, 2, 6 or 24 h. The cells were then harvested and lysed in radioimmunoprecipitation assay buffer (50 m[M]{.smallcaps} Tris, 150 m[M]{.smallcaps} sodium chloride, 1.0 m[M]{.smallcaps} EDTA, 1% Nonidet P40, and 0.25% SDS (pH 7.0)), supplemented with complete protease inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase inhibitor cocktail 1 (Sigma Chemical Co., St Louis, MO, USA). The cells were sonicated briefly, centrifuged at 13 000 × **g** for 20 min at 4 °C, and the supernatant collected. The protein concentration was determined using a Bio-Rad Dc protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Lysates containing 30 *μ*g of protein were run on a 12% acrylamide gel and transferred to a PVDF membrane (Bio-Rad Laboratories). The PVDF membrane was incubated with 5% nonfat dry milk for 1 h at room temperature, then overnight with a primary antibody at 4 °C, and finally with the secondary antibody, horseradish peroxidase (HRP)-conjugated IgG. The SuperSignal West Pico Chemiluminescent Substrate assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA) was used to detect the secondary antibody. For stripping western blots, the blot was incubated with stripping buffer (Pierce Biotechnology Inc.) for 15 min at room temperature.

Rabbit antibodies of caspase-3, caspase-9, XIAP, NIK, NF-*κ*B p65, phospho-NF-*κ*B p65 (Ser536), actin and mouse antibody of caspase-8 were purchased from Cell Signaling Technology (Danvers, MA, USA). The goat antibody of cIAP1 and the mouse antibody of cIAP2 were from R&D Systems (Minneapolis, MN, USA). All the primary antibodies were used at a dilution recommended by the manufacturer. The secondary antibody was HRP-conjugated goat anti-rabbit IgG, HRP-conjugated horse anti-mouse IgG (Cell Signaling Technology) or HRP-conjugated rabbit anti-goat IgG (R&D Systems) at a 1 : 3000, 1 : 10000 or 1 : 1000 dilution, respectively.

Statistical analysis
--------------------

The results are expressed as the mean±s.e.m. based on three independent experiments performed in triplicate. Differences among groups were statistically analysed using a two-tailed Student\'s *t*-test. A *P*-value of \<0.05 was considered significant.

Results
=======

Synthesis of SW IV-52s and SW III-123
-------------------------------------

The syntheses of **SW III-123** and **SW IV-52s** ([@bib12]; [@bib21]) were outlined in [Figure 1](#fig1){ref-type="fig"}. Condensation of commercially available Boc-Pro-OH (**1**) and R-(-)-1,2,3,4-tetrahydro-1-nathylamine (**2**) in the presence of EDCI, DIPEA and HOBt, followed by removal of the Boc-protecting group gave **3**. Condensation of **3** with Boc-Tle-OH, followed by removal of the Boc-protecting group gave **4**. Alkylation of **4** with 2-chloropropionyl chloride gave **5**. Reaction of **5** with amine **SW 43** ([@bib27]) gave the desired product **SW III-123** in 16% yield (overall). Condensation of **4** with Boc-*N*-Me-Ala-OH and removal of the Boc-protecting group gave **SW IV-52s** in 36% yield (overall). **SW III-123** has adequate sigma-2 receptor-binding affinity (*K*~*i,σ2*~ =189.90±12.84 n[M]{.smallcaps}), whereas it has low sigma-1 receptor-binding affinity (*K*~*i,σ1*~=2046.30±62.62 n[M]{.smallcaps}).

SW III-123 potently induced cell death in ovarian cancer cells
--------------------------------------------------------------

SKOV-3 cells were treated with increasing doses of **SW 43**, **SW IV-52s**, a combination of **SW 43** and **SW IV-52s** or **SW III-123** for 24 h, MTS assay were performed to measure the cytotoxicity of these compounds. The results showed that **SW III-123**-induced cell death potently (EC~50~=4.0 *μ*[M]{.smallcaps}) after 24-h treatment, whereas **SW 43**, **SW IV-52s**, or a combination of **SW 43** and **SW IV-52s** significantly shifted the dose-response curve rightward ([Figure 2A](#fig2){ref-type="fig"}). **SW 43** showed cytotoxic effects but at higher doses than **SW III-123**. **SW IV-52s** showed minor cytotoxicity after 24-h treatment (EC~50~ \>100 *μ*[M]{.smallcaps}), but exhibited potent cytotoxicity after 48-h treatment (EC~50~=0.7 *μ*M) in SKOV-3 cells ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The results suggest that **SW IV-52s** does not penetrate cells efficiently during 24-h treatment and the sigma-2 moiety in **SW III-123** delivers the SMC moiety into SKOV-3 cells effectively.

Viability assays were also performed in two other human ovarian cancer cell lines, CaOV-3 and BG-1 ([Figures 2B and C](#fig2){ref-type="fig"}, and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The EC~50~ values for these compounds in three human ovarian cell lines are shown in [Table 1](#tbl1){ref-type="table"}. The results showed that **SW IV-52s** had no cytotoxicity in these two cell lines, whereas **SW III-123** showed potent cytotoxicity, suggesting that sigma-2 moiety of **SW III-123** delivers the SMC moiety into SMC-insensitive cell lines.

In order to study if the entry of **SW III-123** into SKOV-3 cells is mediated by sigma-2 receptors, we examined whether **SW III-123** can block internalisation of **SW 120**, a fluorescent sigma-2 probe, into cells. SKOV-3 cells were pre-treated with **SW 43**, **SW IV-52s** or **SW III-123** for 30 min, and then incubated with **SW 120** for another 30 min. Internalisation of **SW 120** was analysed by flow cytometer. The results showed that **SW 43** and **SW III-123** blocked the internalisation of **SW 120** by 40% and 57%, respectively, whereas **SW IV-52s** did not block the internalisation ([Figure 2D](#fig2){ref-type="fig"}). The data suggest that the sigma-2 ligand delivers SMC into the cells, in fairly large part, through sigma-2 receptor-mediated mechanism.

SW IV-52s and SW III-123, but not SW 43, rapidly degraded cIAP1 and cIAP2
-------------------------------------------------------------------------

In order to study the mechanisms of cell killing by **SW III-123**, we studied effects of this compound on protein levels of IAPs. SKOV-3 cells were treated with 0, 1, 3 and 10 *μ*[M]{.smallcaps} of **SW 43**, **SW IV-52s** or **SW III-123** for 24 h. Western blot data showed that **SW IV-52s** and **SW III-123** markedly decreased cIAP1 and cIAP2 protein levels in a dose-dependent manner ([Figure 3A](#fig3){ref-type="fig"}). **SW IV-52s** and **SW III-123** slightly decreased XIAP expression as the drug concentration increased. **SW 43** did not have any effect on cIAP1, cIAP2 or XIAP protein levels. We also treated SKOV-3 cells with 3 *μ*[M]{.smallcaps} of **SW 43**, **SW IV-52s** or **SW III-123** for 0, 0.5, 2, 6 and 24 h. The western blot results showed that **SW IV-52s** and **SW III-123**, but not **SW 43**, induced rapid degradation of cIAP1 and cIAP2, which occurred as early as 0.5 h, the earliest time point tested after drug treatment. In contrast, none of the three compounds significantly affected XIAP protein levels at any time point. The data suggest that the sigma-2 ligand moiety of **SW III-123** does not have a role either in cIAP1/2 degradation or its downstream signalling, and it functions as a drug delivery agent. The **SW IV-52s** moiety of **SW III-123** is responsible for cIAP1/2 degradation and subsequent cell killing mechanisms.

SW IV-52s and SW III-123, but not SW 43, cleaved pro-caspase-8, -9 and -3
-------------------------------------------------------------------------

XIAP has been shown to be a potent inhibitor of caspase-9 and caspase-3. Both cIAP1 and cIAP2 are implicated in suppression of caspase-8 activation during TNF*α* signalling ([@bib4]; [@bib33]). Therefore, we studied if **SW IV-52s** or **SW III-123** induced caspase-8, -9 and -3 activation by western blot analysis. The data showed that **SW IV-52s** and **SW III-123**, but not **SW43**, triggered pro-caspase-8, -9 and -3 cleavage in a dose-dependent manner after 24-h treatment ([Figure 3A](#fig3){ref-type="fig"}). In all, 3 *μ*[M]{.smallcaps} of **SW IV-52s** or **SW III-123**, but not **SW 43**, induced pro-caspase-8, -9 and -3 cleavage in a time-dependent manner ([Figure 3B](#fig3){ref-type="fig"}). These data suggest that **SW IV-52s** and **SW III-123** activated both intrinsic and extrinsic apoptotic pathways.

SW IV-52s and SW III-123, but not SW 43, induced NF-*κ*B activation and TNF*α*-dependent apoptosis
--------------------------------------------------------------------------------------------------

cIAP1 and cIAP2 were originally identified by their association with TNFR2 via TRAF1 and TRAF2 ([@bib16]; [@bib26]). It has been suggested that degradation of cIAP1 and cIAP2 by SMC activates NF-*κ*B pathway and induces production of TNF*α*, a target of NF-*κ*B transcription factors. Therefore, we examined if **SW IV-52s** or **SW III-123** induced NF-*κ*B activation in SKOV-3 cells. Western blot results showed that **SW IV-52s** and **SW III-123**, but not **SW 43,** induced phosphorylation of NF-*κ*B p65 in a dose-dependent manner after 24-h treatment ([Figure 4A](#fig4){ref-type="fig"}). In all, 3 *μ*[M]{.smallcaps} of **SW IV-52s** or **SW III-123** induced phosphorylation of NF-*κ*B p65 in a time-dependent manner ([Figure 4B](#fig4){ref-type="fig"}). Phosphorylation of NF-*κ*B p65 occurred as early as 5 min after treatment with **SW III-123** ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). These data suggest that canonical NF-*κ*B signalling pathway is activated. The data also showed that **SW IV-52s** and **SW III-123**, but not **SW 43**, induced NF-*κ*B-inducing kinase (NIK) accumulation in a dose-dependent manner after 24-h treatment. In total, 3 *μ*[M]{.smallcaps} of **SW IV-52s** or **SW III-123** significantly increased NIK protein level ([Figure 4B](#fig4){ref-type="fig"}) in a time-dependent manner. The results suggest that noncanonical NF-*κ*B signalling pathway is activated.

In order to examine if the cell death induced by **SW IV-52s** or **SW III-123** is TNF*α* dependent, we measured caspase-3 activity in a cell-based assay in the presence or absence of TNF*α* antibody. SKOV-3 cells were pre-treated with or without 2 *μ*g ml^--1^ TNF*α* antibody for 1 h, and then treated with 3 *μ*[M]{.smallcaps} **SW IV-52s**, **SW 43** or **SW III-123** for 24h. The cells were assayed for caspase-3 activity. The data showed that **SW IV-52s** and **SW III-123**, but not **SW 43**, induced caspase-3 activity, and TNF*α* antibody markedly blocked caspase-3 activation induced by either compound ([Figure 5A](#fig5){ref-type="fig"}). We also performed MTS viability assay in the presence or absence of TNF*α* antibody. We showed that TNF*α* antibody significantly blocked cell death induced by 3 or 10 *μ*[M]{.smallcaps} **SW IV-52s** ([Figure 5C](#fig5){ref-type="fig"}) or by 3 *μ*[M]{.smallcaps} **SW III-123** ([Figure 5D](#fig5){ref-type="fig"}). These data suggest that **SW IV-52s** and **SW III-123** induced TNF*α*-dependent apoptosis in SKOV-3 cells.

TNF*α* antibody blocking experiments were also performed in SMC-insensitive ovarian cell lines, CaOV-3 and BG-1. We have shown that **SW III-123** induced caspase-3 activation and cell death in these two cell lines. However, unlike in SKOV-3 cells, TNF*α* antibody did not block **SW III-123** induced caspase-3 activation and cell death in CaOV-3 and BG-1 cells ([Supplementary Figures 3 and 4](#sup1){ref-type="supplementary-material"}), suggesting that **SW III-123** induced TNF*α*-independent cell death in SMC-insensitive cell lines.

Discussion
==========

A major limitation of conventional chemotherapy is toxicity of anticancer drugs to normal tissues. Development of tumour-targeted drug delivery agent represents an important strategy to overcome this problem. By using PET imaging technology, our laboratory has shown that ^18^F-labelled sigma-2 ligand specifically bind to tumours in mouse models ([@bib25]) and in human clinical studies ([@bib3]). In addition, we have demonstrated that fluorescent sigma-2 ligands are rapidly internalised into cancer cells by endocytosis ([@bib40], [@bib39]). These findings led us to propose that sigma-2 ligands can be used as a tumour-targeting drug delivery agent.

In this study, we evaluated this strategy by synthesising a sigma-2 ligand-conjugated drug and studying its cell killing mechanisms. We have attached a sigma-2 ligand, **SW 43**, to an anticancer drug, **SW IV-52s** to form **SW III-123**. It was reported that **SW IV-52s** binds to BIR3 domain of XIAP with high affinity (*K*~*d*~=12 n[M]{.smallcaps}) and is effective in rescuing XIAP BIR3-mediated inhibition of caspase activity in a cell-free functional assay ([@bib12]; [@bib21]). We showed that **SW IV-52s** treatment for 24 h induced minor cytotoxicity (EC~50,24h~ \>100 *μ*[M]{.smallcaps}) in SKOV-3 cells, whereas **SW III-123-**induced cell death potently (EC~50,24h~=4.0 *μ*[M]{.smallcaps}). We also showed that **SW IV-52s** did not exhibit cytotoxicity in CaOV-3 and BG-1 cells, whereas **SW III-123** strongly induced cell death in both cell lines ([Table 1](#tbl1){ref-type="table"}, [Figure 2](#fig2){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). The strong cell killing potency of **SW III-123** is not due to the additive or synergistic effects of **SW 43** and **SW IV-52s**, because the combination of these two compounds induced much less cytotoxicity than the covalently conjugated compound, **SW III-123** ([Figure 2A](#fig2){ref-type="fig"}). The data suggest that the sigma-2 ligand (**SW 43**) moiety of **SW III-123** delivers the SMC moiety into cancer cells. Multiple mechanisms may be responsible for the potent cytotoxicity of **SW III-123**. (1) Compared with **SW IV-52s,** the intracellular concentration of the SMC moiety of **SW III-123** could be increased because of sigma-2 receptor-mediated delivery mechanisms. (2) The subcellular localisation of the SMC moiety of **SW III-123** could be different from that of **SW IV-52s**. Previously, we have shown that a sigma-2 fluorescent probe, **SW120**, which is an analogue of **SW 43**, is internalised into cells through endocytotic mechanisms and distributed in mitochondria, endoplasm reticulum and lysosome ([@bib39]). It is possible that the **SW 43** moiety directs the SMC moiety into the **SW 43**-targeted subcellular organelles where the SMC moiety could interact with IAPs and induce cell death. (3) The SMC moiety of **SW III-123** could potentiate the cytotoxicity of the **SW 43** moiety. [Figure 2](#fig2){ref-type="fig"} showed that **SW 43** was cytotoxic although at concentrations much higher than **SW III-123**. The mechanisms of **SW 43**-elicited cytotoxicity was reported recently. **SW 43** induced lysosomal membrane permeabilisation, cathepsin B leakage from lysosome, cellular oxidative stress and caspase-3-independent apoptosis ([@bib9]). The cytotoxic effects of the SMC moiety could make cells more susceptible to the cytotoxicity of the **SW 43** moiety. These possible mechanisms deserve further study.

Previous studies demonstrated that SMCs display cell killing effects only in a subset of cell lines ([@bib21]). Our data showed that **SW IV-52s** exhibited cytotoxicity in SKOV-3 cells, but not in CaOV-3 or BG-1 cells ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). However, **SW III-123** showed potent cytotoxicity in all of the three cell lines. These data suggest that the sigma-2 ligand can deliver SMC into both SMC-sensitive and SMC-insensitive cell lines, expanding the application of SMCs as antitumour agents in more tumour types. We showed that **SW III-123** had adequate sigma-2 receptor-binding affinity (*K*~*i,σ2*~=189.90 n[M]{.smallcaps}), and significantly blocked internalisation of a fluorescent sigma-2 ligand, **SW 120**, in SKOV3 cells ([Figure 2D](#fig2){ref-type="fig"}), indicating that the delivery of SMC into tumour cells by the sigma-2 ligand is mediated by sigma-2 receptors. Collectively, these results provided the proof-of-concept for sigma-2 receptor-targeted drug delivery.

In order to study the cell death mechanisms induced by **SW III-123** and **SW IV-52s**, we first examined if these compounds affect IAP protein levels. We showed that both compounds induced decreases in cIAP1 and cIAP2 protein levels as early as 0.5 h at 3 *μ*[M]{.smallcaps}, but had little effect on XIAP protein level within 24-h treatment ([Figures 3A and B](#fig3){ref-type="fig"}). It is reported that cIAP1 and cIAP2 are ubiquitin E3 ligases, and SMC triggers auto-ubiquitination and subsequent proteasomal degradation of cIAP1 and cIAP2 ([@bib28]). Thus, it is possible that **SW III-123** and **SW IV-52s** bind to BIR3 of cIAP1 and cIAP2, and change their conformation, which allows the ubiquitination and subsequent proteasomal degradation. We then studied if **SW III-123** and **SW IV-52s** triggers apoptosis. Western blot results showed that pro-caspase-8, -9 and -3 were cleaved ([Figures 3A and B](#fig3){ref-type="fig"}) by the treatment of these compounds, suggesting that both extrinsic and intrinsic apoptotic pathways were activated.

Several studies have demonstrated that SMC induces NF-*κ*B activation and TNF*α*-dependent cell death ([@bib13]; [@bib28]; [@bib32]). NF-*κ*B family transcription factors regulate the transcription of a vast array of proteins in cell survival, proliferation and inflammatory response ([@bib8]; [@bib22]). The NF-*κ*B signalling pathways can be classified into canonical and noncanonical pathways. In the canonical NF-*κ*B pathway, NF-*κ*B family members form heterodimers, such as p50/p65 dimer. In unstimulated cells, p50/p65 dimers are sequestered in the cytoplasm by interaction with inhibitors of NF-*κ*B (I*κ*B). In the presence of stimuli, I*κ*B kinase (IKK) phosphorylates I*κ*B*α*, triggering its degradation; this leads to the translocation of p50/p65 dimers into the nucleus to regulate transcription. In the noncanonical NF-*κ*B pathway ([@bib22]), in the absence of noncanonical NF-*κ*B inducers, newly synthesised NIK is rapidly bound by TRAF3 and targeted to TRAF-cIAP ubiquitin ligase complex, where cIAP1 and cIAP2 catalyse ubiquitination of NIK through their ubiquitin E 3 ligase activity, targeting NIK for degradation in the proteasome. In cells stimulated by noncanonical signals, NIK is accumulated and activated. NIK activates IKK*α*, leading to p100 processing to p52 subunit and nuclear translocation of NF-*κ*B heterodimer p52/RelB to regulate transcription. In this study, we showed that **SW III-123** and **SW IV-52s** rapidly induced NIK accumulation ([Figure 4B](#fig4){ref-type="fig"}), and NIK accumulation peaked after cIAP1 and cIAP2 degradation ([Figures 3B](#fig3){ref-type="fig"} and [4B](#fig4){ref-type="fig"}). It is likely that degradation of cIAP1 and cIAP2 upon the treatment of **SW III-123** and **SW IV-52s** prevents ubiquitination of NIK by cIAP1 and cIAP2 and its proteasomal degradation, leading to NIK stabilisation and activation of the noncanonical NF-*κ*B signalling pathway. In addition, we showed that **SW III-123** and **SW IV-52s** induced phosphorylation of NF-*κ*B p65 as early as 5 min after the treatment ([Figures 4A and B](#fig4){ref-type="fig"}, and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). It is reported that phosphorylation of NF-*κ*B p65 is required for an optimal activation of canonical NF-*κ*B signalling ([@bib29]). Thus, our data suggest that canonical NF-*κ*B pathway is activated as well. As shown in [Figures 4A and B](#fig4){ref-type="fig"}, **SW IV-52s** induced more NIK accumulation than **SW III-123**. **SW IV-52s** is an optically active compound, containing an (*S*)-alanyl group, whereas **SW III-123** is a racemic compound (i.e., *R/S*-alanyl group). It is possible that only one enantiomer of **SW III-123** is biologically active and the racemic **SW III-123** is not as effective as **SW IV-52s** in inducing NIK accumulation. The positive results described in this study led to our devising a new synthetic route for preparing optically pure **SW III-123**. Future studies with this compound will utilise the optically pure compound.

TNF*α* is one of the target genes for NF-*κ*B transcription factors. We determined if the cell death induced by **SW III-123** and **SW IV-52s** is TNF*α* dependent. We showed that TNF*α* antibody markedly inhibited caspase-3 activation and cell death induced by both compounds ([Figures 5A--D](#fig5){ref-type="fig"}) in SKOV-3 cells. These data indicated that NF-*κ*B-induced TNF*α* is a key player in **SW III-123** and **SW IV-52s**-triggered cell death. The binding of TNF*α* to TNFR1 has been shown to initiate the extrinsic apoptotic pathway ([@bib1]). The binding of TNF*α* to TNFR1 recruits Fas-associated death domain protein, Fas-associated death domain protein and caspase-8. Upon recruitment, caspase-8 is activated by self-cleavage, and then activates caspase-3. It is possible that **SW III-123** and **SW IV-52s** triggered caspase-8 and -3 cleavage ([Figure 3](#fig3){ref-type="fig"}) through sequential events of activation of NF-*κ*B, TNF*α* production and TNF*α*-induced extrinsic apoptotic pathway.

Our data showed that TNF*α* antibody did not block **SW III-123** induced caspase-3 activation and cytotoxicity in SMC-insensitive ovarian cell lines, CaOV-3 and BG-1 ([Supplementary Figure 3 and 4](#sup1){ref-type="supplementary-material"}), suggesting that **SW III-123** induced TNF*α*-independent cell death. The data are consistent with the previous report that SMC does not induce TNF*α* production in SMC-insensitive cell lines ([@bib32]). It is not clear why some cells are SMC-sensitive and some are not. The molecular mechanisms of **SW III-123**-induced cell death in SMC-insensitive cells deserve further studies. Sigma-2 ligand-conjugated SMC may offer a new class of drugs for treating SMC-insensitive cancer cells. We showed that **SW III-123** and **SW IV-52s** induced caspase-9 cleavage, suggesting that intrinsic apoptotic pathway is activated. One possible mechanism for caspase-9 activation is that the activated caspase-8 via extrinsic pathway engages the intrinsic pathway by cleaving the proapoptotic BCL-2 family member BID (BH3 interacting-domain death agonist). It is reported that during extrinsic apoptosis caspase-8 is enriched on the mitochondrial surface and form native complex with BID in some cell types ([@bib17]). Following extrinsic apoptotic stimuli, active caspase-8 cleaves BID. The cleaved BID interacts with other BCL-2 family members on the surface of the mitochondria, which results in mitochondrial outer membrane permeabilisation, cytochome c release, apoptosome assembly, caspase-9 cleavage and subsequent caspase-3 activation. XIAP binds and inhibits caspase-9 through its BIR3 domain ([@bib18]), whereas SMCs such as **SW III-123** or **SW IV-52s** have been shown to bind XIAP BIR3 and remove the inhibition of XIAP for caspase-9, thereby promoting apoptosis.

On the basis of our data and the findings in the literature, we propose a model for **SW III-123**-induced cell death signalling pathways in SMC-sensitive cell lines ([Figure 6](#fig6){ref-type="fig"}). **SW III-123** is internalised into cells via sigma-2 receptor-mediated endocytosis. Upon entering cells, **SW III-123** binds to cIAP1 and cIAP2 in their BIR3 domain and induces rapid degradation of cIAP1 and cIAP2 and accumulation of NIK, which initiates noncanonical NF-*κ*B pathway. Canonical NF-*κ*B signalling is also activated as **SW III-123** induced phosphorylation of NF-*κ*B p65 ([Figure 4](#fig4){ref-type="fig"}). The activation of NF-*κ*B transcription factor induces expression of TNF*α*, which then binds to TNFRs and triggers the extrinsic apoptotic pathway, resulting in caspase-8 activation and subsequent caspase-3 activation. Active caspase-8 in turn triggers the intrinsic apoptotic pathway presumably via cleaving BID on the surface of mitochondria, leading to caspase-9 and -3 activation. **SW III-123** binds to XIAP BIR3, which disrupts interaction of XIAP and caspase-9, and thus activates caspase-9 and caspase-3. In summary, **SW III-123** delivers SMC into ovarian cancer cells and then binds to IAPs and induces TNF*α*-dependent apoptosis.

Conjugating a sigma-2 ligand to an anticancer drug provides a platform for delivering drugs selectively into tumour cells. The sigma-2 receptor ligand may be exploited to carry any cytotoxic drug or drug-loaded nanoparticles to various tumours that overexpress the sigma-2 receptor. Sigma-2 receptor ligand-linked therapeutic agents will likely display reduced off-site toxicity and enhanced potency against tumour cells. These features could lead to improved treatment regimens and cancer patient outcomes.
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![**The synthetic schemes for generating SW III-123 (A) and SW IV-52s (B).**](bjc2013593f1){#fig1}

![**SW III-123 potently induced cell death in ovarian cancer cells.** SKOV-3 (**A**), CaOV-3 (**B**) or BG-1 (**C**) cells were treated with increasing concentrations of **SW 43** (○), **SW IV-52s** (●), the combination of **SW 43** and **SW IV-52s** (□), or **SW III-123** (▪) for 24 h. Cell viability was determined by MTS assay. (**D**) Flow cytometric determination of the internalisation of **SW120** in SKOV-3 cells with the blocking compound of **SW 43** (▪), **SW IV-52s** (▴) or **SW III-123** (●). The bars represent mean±s.e.m. in at least three independent experiments.](bjc2013593f2){#fig2}

![**SW IV-52s and SW III-123 rapidly degraded cIAP1 and cIAP2 and cleaved pro-caspase-8, -9, and -3. (A) SKOV-3 cells were treated with 0, 1, 3 and 10 *μ*[M]{.smallcaps} SW 43, SW IV-52s or SW III-123 for 24 h.** The whole-cell lysates were analysed by western blot. (**B**) SKOV-3 cells were treated with 3 *μ*[M]{.smallcaps} of **SW 43**, **SW IV-52s** or **SW III-123** for indicated time. The whole-cell lysates were analysed by western blot.](bjc2013593f3){#fig3}

![**SW IV-52s and SW III-123 induced NF-*κ*B activation.** (**A**) SKOV-3 cells were treated with 0, 1, 3 and 10 *μ*[M]{.smallcaps} **SW 43**, **SW IV-52s** or **SW III-123** for 24 h. The whole-cell lysates were analysed by western blot. (**B**) SKOV-3 cells were treated with 3 *μ*[M]{.smallcaps} of **SW 43**, **SW IV-52s** or **SW III-123** for indicated time. The whole-cell lysates were analysed by western blot.](bjc2013593f4){#fig4}

![**SW IV-52s and SW III-123 induced TNF*α*-dependent apoptosis.** (**A**) SKOV-3 cells were pre-treated with or without 2 *μ*g ml^--1^ TNF*α* antibody for 1 h, and then treated with 3 *μ*[M]{.smallcaps} **SW IV-52s, SW 43** or **SW III-123** for 24 h. The cells were assayed for caspase 3 activity. (**B**--**D**) SKOV-3 cells were pre-treated with or without 2 *μ*g ml^--1^ TNF*α* antibody for 1 h, and then treated with 3 or 10 *μ*[M]{.smallcaps} **SW 43** (**B**), **SW IV-52s** (**C**) or **SW III-123** (**D**) for 48 h. Viability of cells was determined by MTS assay. The representative data from three independent experiments are shown. \**P*\<0.05.](bjc2013593f5){#fig5}

![**A model for cell death signalling pathways induced by SW III-123.** **SW III-123** is internalised cells through sigma-2 receptor (*σ*2R)-mediated endocytosis. **SW III-123** degrades cIAP1 and cIAP2, and thus antagonises cIAP1/2-mediated NF-*κ*B-inducing kinase (NIK) degradation, induces nuclear factor (NF)-*κ*B activation and subsequent tumour necrosis factor alpha (TNF*α*) production. TNF*α* binds to TNFR and induces extrinsic and intrinsic apoptotic pathways, leading to caspase-8, -9 and -3 activation. **SW III-123** also binds to XIAP, and thus removes the inhibition of XIAP to caspase-9, promoting apoptosis. IAP, inhibitor of apoptosis protein.](bjc2013593f6){#fig6}

###### Cytotoxicity of **SW 43**, **SW IV-52s** and **SW III-123** in human ovarian cancer cells

                                  **SKOV-3**                               **SKOV-3**                               **CaOV-3**                               **CaOV-3**                                **BG-1**                                 **BG-1**
  ---------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ----------------------------------------
  **Compound**      EC~50~±s.e. (*μ*[M]{.smallcaps}, 24 h)   EC~50~±s.e. (*μ*[M]{.smallcaps}, 48 h)   EC~50~±s.e. (*μ*[M]{.smallcaps}, 24 h)   EC~50~±s.e. (*μ*[M]{.smallcaps}, 48 h)   EC~50~±s.e. (*μ*[M]{.smallcaps}, 24 h)   EC~50~±s.e. (*μ*[M]{.smallcaps}, 48 h)
  **SW 43**                        25.2±0.7                                 19.7±0.8                                 15.9±1.1                                 14.0±0.5                                 24.0±0.9                                 24.1±2.1
  **SW IV-52s**                     \>100                                   0.7±0.1                                   \>100                                    \>100                                    \>100                                    \>100
  **SW III-123**                   4.0±0.6                                  1.4±0.3                                  2.8±0.1                                  1.3±0.1                                  2.3±0.1                                  1.3±0.1

[^1]: These authors contributed equally to this work.
